Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorMutlu, Hasan
dc.contributor.authorGunduz, Seyda
dc.contributor.authorKaraca, Halit
dc.contributor.authorBuyukcelik, Abdullah
dc.contributor.authorCihan, Yasemin Benderli
dc.contributor.authorErden, Abdulsamet
dc.contributor.authorAkca, Zeki
dc.contributor.authorCoskun, Hasan Senol
dc.date.accessioned2025-10-16T15:32:43Z
dc.date.issued2014
dc.identifier.doi10.1007/s12032-014-0074-9
dc.identifier.otherWOS:000340095700055
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/9169
dc.publisherHUMANA PRESS INC
dc.sourceMEDICAL ONCOLOGY
dc.subjectMesothelioma
dc.subjectGemcitabine
dc.subjectSecond\\-line
dc.subjectSurvival
dc.titleSecond-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS